GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Keryx Biopharmaceuticals, Inc. (KERX) [hlAlert]

Rating:
Mkt Outperform
KERX
up 134.84 %

Keryx Biopharmaceuticals, Inc. (KERX) rated Mkt Outperform with price target $8 by Rodman & Renshaw

Posted on: Wednesday,  May 12, 2010  2:25 PM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) on 05/12/2010. Previously Rodman & Renshaw rated Mkt Outperform Keryx Biopharmaceuticals, Inc. (NASDAQ:
KERX) on 03/01/2010., when the stock price was $2.64. Since then, Keryx Biopharmaceuticals, Inc. has gained 134.85% as of 01/12/2016's recent price of $6.20.
If you would have followed the previous Rodman & Renshaw's recommendation on KERX, you would have gained 134.84% of your investment in 2143 days.

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/12/2010 2:25 PM Buy
None
5.99 8.00
as of 12/31/2010
1 Week down  -18.43 %
1 Month down  -29.48 %
3 Months down  -19.95 %
1 YTD down  -41.32 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/1/2010 4:25 PM Buy
None
2.64 6.00
3/10/2008 8:25 AM Sell
None
0.64 2.30

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy